Could an Anti-Inflammatory pill slow Parkinson's?
NCT ID NCT07157735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether dapansutrile, a drug that targets inflammation, is safe and can reduce brain and body inflammation in people with early Parkinson's disease. 36 participants will take either the drug or a placebo daily for 6 months, with brain scans and spinal taps to measure effects. The goal is to see if calming inflammation might help modify the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- dapansutrile
- What this could lead to
- If it works, this could point toward a new way to slow Parkinson's progression by targeting inflammation.
- What could go wrong
- This is a small early-phase trial with only 36 people, so results may not apply widely. The drug may not reduce inflammation or improve symptoms, and side effects are unknown.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
John Van Geest Centre for Brain Repair
RECRUITINGCambridge, CB2 0PY, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Planning ahead: could a simple program transform Parkinson's care?
- Sound waves vs. Parkinson's: can ultrasound calm tremors and stiffness?
- Can a nudge in your chart unlock Life-Saving genetic clues?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Can we outsmart Gaucher's hidden toll on lungs, bones, and brain?
- Could a brain disease change behavior years before diagnosis?